Cerebral Embolic Protection Devices (CEPDs) During Transcatheter Aortic Valve Implantation (TAVI): A Meta-Analysis of Randomized Controlled Trials

Theodor Bilharz Research Institute

Bibliographic Information

Authors: Gbreel M.I.; Badran A.S.; Hassan M.; Balata M.

Journal: Clinical Cardiology

Publisher: John Wiley and Sons Inc

Publication Date: 23 April 2026

Volume / Issue: Volume 49 / Issue 4

Article No.: e70309

ISSN: 1609289

DOI: 10.1002/clc.70309

Scopus: View on Scopus

PubMed: 42021683

Document Type: Review

Access: All Open Access; Gold Open Access; Green Open Access


Authors and Affiliations

Gbreel M.I., Faculty of Medicine, October 6 University, Giza, Egypt; Badran A.S., Faculty of Medicine, Ain Shams University, Cairo, Egypt; Hassan M., Theodor Bilharz Research Institute, Giza, Egypt; Balata M., Department of Cardiology, University Hospital Rostock, Rostock, Germany


Abstract

Aims: Transcatheter aortic valve implantation (TAVI) is associated with procedure-related stroke. Cerebral embolic protection devices (CEPDs) are designed to reduce the risk of embolic debris reaching the brain; however, the evidence supporting their efficacy remains controversial. We aim to evaluate the efficacy and safety of CEPDs in patients undergoing TAVI. Methods: Major databases were systematically searched up to April 2025. Only randomized controlled trials (RCTs) were included and critically appraised using the Cochrane Risk of Bias (ROB-2) tool. We calculated risk ratios (RRs) with the 95% confidence intervals for the outcomes, and trial sequential analysis (TSA) was conducted to reduce the risk of false-positive results due to random errors. Results: Eight RCTs (11,589 patients) were analyzed. No significant difference was observed in overall stroke incidence between CEPD and control groups (0.92 (95% CI: 0.75–1.14; p = 0.40, I2 = 0%), including disabling and non-disabling strokes. Device-specific analyses showed a non-significant reduction in disabling stroke with the Sentinel device. All-cause mortality, transient ischemic attacks, bleeding, acute kidney injury, delirium, and pacemaker implantation rates were similar between groups. CEPD use was linked to a transient improvement in cognitive function (MoCA scores) at 2–5 days post-TAVI, but this effect was not sustained at later follow-ups. TSA indicated that current evidence is insufficient to definitively refute CEPD efficacy. Conclusion: CEPDs show no significant reduction in overall, disabling, or non-disabling stroke, nor in all-cause mortality post-TAVI. Trial Registration: This meta-analysis was registered on PROSPERO. No.: CRD420251026208. © 2026 The Author(s). Clinical Cardiology published by Wiley Periodicals LLC.


Keywords

cerebral embolic protection; meta-analysis; stroke; TAVI; transcatheter aortic valve implantation; Aortic Valve; Aortic Valve Stenosis; Embolic Protection Devices; Humans; Intracranial Embolism; Randomized Controlled Trials as Topic; Risk Factors; Transcatheter Aortic Valve Replacement; Treatment Outcome; adverse event; brain embolism; cerebrovascular accident; embolic protection device; epidemiology; etiology; human; meta analysis; prevention and control; randomized controlled trial (topic); risk factor; surgery


Citation Information

Scopus Citations: 0


For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.

The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.

English Website: https://www.tbri.sci.eg/en/

Arabic Website: https://www.tbri.sci.eg/ar/

Prepared and Uploaded by:

Abdalla F. Abdalla

Electronic Portal Unit

Electronic Portal Unit

Popular Posts

Transcriptome analysis for Schistosoma vector snail’s Oncomelania hupensis exposed to silver nanoparticles

Interpretation of liver stiffness measurement in patients with mixed liver disease etiologies

Multifunctional polycaprolactone-based composite fibers with icariin and glutathione for effective repair of critical-sized bone defects

Holothuria arenicola Extract-Loaded Polycaprolactone Nanocapsules Attenuate Bile Duct Ligation-Induced Acute Liver Injury

Mytilus edulis-mediated green synthesis of selenium nanoparticles with antimicrobial and molluscicidal applications

Microbial levan potentiates hepatic retention and antitumor activity of a PEGylated benzimidazole–curcumin nanocomplex through TLR2–FXR/FGF15-associated immunometabolic remodeling in experimental liver cancer

Variable clinical presentations of pulmonary hydatid cysts: a four-case series from a single center in United Arab Emirates, non-endemic region